Opinion|Videos|October 1, 2024
Multi-Modal Treatment Strategy for HFmrEF and HFpEF
Author(s)Javed Butler, MD, MPH, MBA
Javed Butler, MD, MPH, MBA, discusses the additional benefits of combining finerenone with sodium-glucose cotransporter-2 inhibitors for treating heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF as well as how a multimodal approach used in HF with reduced EF can be adapted for managing these conditions.
Advertisement
Video content above is prompted by the following:
- What additional benefits does adding finerenone offer when combined with sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with midrange ejection fraction (HFmrEF) and HF with preserved EF (HFpEF)?
- When considering the multimodal approach for the treatment of HF with reduced EF, how can that strategy now be implemented for the management of HFmrEF and HFpEF?
- What results were presented?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
4
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
5